Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.

Fifty-one patients with advanced non-small cell lung carcinoma were treated with a combination of mitomycin C, vinblastine and cis-platin (MVP). Most cycles were given on an out-patient basis. Major side effects were leukopenia and peripheral neurotoxicity; one patient died of sepsis while leukopeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Giaccone, G., Bagatella, M., Donadio, M., Bonardi, G. M., Testore, F., Ferrati, P., Ciuffreda, L., Calciati, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001818/
https://www.ncbi.nlm.nih.gov/pubmed/2825750
_version_ 1782135673382240256
author Giaccone, G.
Bagatella, M.
Donadio, M.
Bonardi, G. M.
Testore, F.
Ferrati, P.
Ciuffreda, L.
Calciati, A.
author_facet Giaccone, G.
Bagatella, M.
Donadio, M.
Bonardi, G. M.
Testore, F.
Ferrati, P.
Ciuffreda, L.
Calciati, A.
author_sort Giaccone, G.
collection PubMed
description Fifty-one patients with advanced non-small cell lung carcinoma were treated with a combination of mitomycin C, vinblastine and cis-platin (MVP). Most cycles were given on an out-patient basis. Major side effects were leukopenia and peripheral neurotoxicity; one patient died of sepsis while leukopenic. In 44 evaluable patients the response rate was 50%, with one complete response. Overall median survival time was 280 days and median duration of responses was 232 days. A better performance status, disease limited to one hemithorax and no prior exposure to chemotherapy positively influenced the survival. MVP is an effective chemotherapy for non-small cell lung cancer and further experience with this combination is warranted.
format Text
id pubmed-2001818
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20018182009-09-10 Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer. Giaccone, G. Bagatella, M. Donadio, M. Bonardi, G. M. Testore, F. Ferrati, P. Ciuffreda, L. Calciati, A. Br J Cancer Research Article Fifty-one patients with advanced non-small cell lung carcinoma were treated with a combination of mitomycin C, vinblastine and cis-platin (MVP). Most cycles were given on an out-patient basis. Major side effects were leukopenia and peripheral neurotoxicity; one patient died of sepsis while leukopenic. In 44 evaluable patients the response rate was 50%, with one complete response. Overall median survival time was 280 days and median duration of responses was 232 days. A better performance status, disease limited to one hemithorax and no prior exposure to chemotherapy positively influenced the survival. MVP is an effective chemotherapy for non-small cell lung cancer and further experience with this combination is warranted. Nature Publishing Group 1987-10 /pmc/articles/PMC2001818/ /pubmed/2825750 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Giaccone, G.
Bagatella, M.
Donadio, M.
Bonardi, G. M.
Testore, F.
Ferrati, P.
Ciuffreda, L.
Calciati, A.
Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.
title Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.
title_full Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.
title_fullStr Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.
title_full_unstemmed Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.
title_short Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.
title_sort mitomycin c, vinblastine and cis-platin. an active regimen for advanced non-small cell lung cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001818/
https://www.ncbi.nlm.nih.gov/pubmed/2825750
work_keys_str_mv AT giacconeg mitomycincvinblastineandcisplatinanactiveregimenforadvancednonsmallcelllungcancer
AT bagatellam mitomycincvinblastineandcisplatinanactiveregimenforadvancednonsmallcelllungcancer
AT donadiom mitomycincvinblastineandcisplatinanactiveregimenforadvancednonsmallcelllungcancer
AT bonardigm mitomycincvinblastineandcisplatinanactiveregimenforadvancednonsmallcelllungcancer
AT testoref mitomycincvinblastineandcisplatinanactiveregimenforadvancednonsmallcelllungcancer
AT ferratip mitomycincvinblastineandcisplatinanactiveregimenforadvancednonsmallcelllungcancer
AT ciuffredal mitomycincvinblastineandcisplatinanactiveregimenforadvancednonsmallcelllungcancer
AT calciatia mitomycincvinblastineandcisplatinanactiveregimenforadvancednonsmallcelllungcancer

Ejemplares similares